Smartcupri self-healing amphi-hydrogel for advanced skin repair
SmartCupri is an amphibian-derived collagen hydrogel designed for chronic wound treatment and full-fledged skin repair. By upcycling collagen waste and integrating bioactive adjuvants, this smart dressing modulates inflammatory microenvironments and supports natural healing pathways for diabetic and chronic wound patients.
Overview
SmartCupri is an advanced wound care platform built on self-healing amphibian-derived collagen hydrogel technology. The solution targets chronic wounds—defined as wounds failing to heal within six weeks—which affect over 6 million patients annually in the US alone and impose healthcare costs of $20 to $25 billion. By leveraging collagen sourced through waste valorisation, SmartCupri aligns with circular economy principles while addressing a critical and growing medical need driven by ageing populations and conditions such as diabetes.
The hydrogel is designed to modulate inflammatory microenvironments and synergize with the body's inherent healing pathways. Preliminary data supports the feasibility of converting upcycled collagen into a functional hydrogel, with potential for further enhancement through bioactive adjuvants including medicinal herbals, magnetic particles, and biologics such as entomotherapy secretions, probiotics, and growth factors. The goal is full-fledged skin recovery through a reactive, self-healing dressing that responds to changes in the wound microenvironment.
Technical specifications
Core technology:
- Amphibian-derived collagen produced via an established in-house workflow with scalable production capacity
- Collagen sourced through waste valorisation, supporting circular economy frameworks
- Hydrogel matrix with self-healing properties responsive to chronic wound microenvironment changes
- Optional integration of nano-collagen fibres for enhanced structural performance
Potential enhancements:
- Medicinal herbals: Purica, Curcumin, and similar bioactive compounds
- Magnetic particles: magnetite (Fe3O4) or maghemite (Fe2O3) for responsive functionality
- Biologics: insect-derived secretions, probiotics such as L. Plantarum, and growth factors including VEGF and PDGF
Validation procedures:
- Physicochemical characterization via SEM, AFM, FTIR, and SDS-PAGE
- Stability assessment through denaturation profiling
- Cytocompatibility testing in 2D cultures (fibroblasts, keratinocytes) and 3D cultures (Matrigel, Transwell)
- Sterility testing for microbial contamination and endotoxin levels
- Pre-clinical validation in diabetic rat models (approximately 150 subjects across five groups) with wound area assessment, hydroxyproline assays, and histological analysis using IHC, H&E, and Masson's trichrome staining
Technology readiness level
SmartCupri is currently at an early-to-mid stage of development. The amphibian-derived collagen production workflow has been established in-house with demonstrated scalability potential. Preliminary data supports the feasibility of hydrogel conversion and enhancement strategies. Future validation will progress through physicochemical characterization, cytocompatibility studies, sterility testing, and pre-clinical trials in diabetic rat wound models. The development is supported by veterinary expertise and builds upon the organization's existing clinical experience with medical-grade maggot debridement therapy registered as a Medical Device Class C product in Singapore.
About Cuprina Holdings
Cuprina Holdings is a Singapore-based biomedical and biotechnology company focused on harnessing entomology-driven solutions for healthcare, agriculture, and waste management. Its primary medical innovation is MEDIFLY, a bio-dressing therapy utilizing live, medical-grade Lucilia cuprina maggots. These products are designed to clean wound beds and treat chronic wounds, offering a clinically effective and cost-conscious alternative to traditional debridement methods. By integrating biological insights into industrial processes, the company also explores broader applications for its technologies in sustainable development and circular economy solutions.
The company serves healthcare providers, clinics, and hospitals by providing end-to-end wound care solutions intended to improve patient quality of life and reduce the frequency of amputations. Their medical products have demonstrated significant clinical efficacy in local studies, including high rates of limb salvage and wound closure for complex patient populations. Through its leadership in biotechnology and insect-based applications, Cuprina addresses critical medical challenges while simultaneously expanding its capabilities into urban farming and sustainable resource management, aiming to build a future-fit organization that benefits both communities and the planet.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.